Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Brain permeant and impermeant inhibitors of fatty-acid amide hydrolase synergize with the opioid analgesic morphine to suppress chemotherapy-induced neuropathic nociception without enhancing effects of morphine on gastrointestinal transit.

Slivicki RA, Saberi SA, Iyer V, Vemuri K, Makriyannis A, Hohmann AG.

J Pharmacol Exp Ther. 2018 Oct 1. pii: jpet.118.252288. doi: 10.1124/jpet.118.252288. [Epub ahead of print]

2.

Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence.

Slivicki RA, Xu Z, Kulkarni PM, Pertwee RG, Mackie K, Thakur GA, Hohmann AG.

Biol Psychiatry. 2017 Jul 8. pii: S0006-3223(17)31761-4. doi: 10.1016/j.biopsych.2017.06.032. [Epub ahead of print]

PMID:
28823711
3.

The chemotherapeutic agent paclitaxel selectively impairs learning while sparing source memory and spatial memory.

Smith AE, Slivicki RA, Hohmann AG, Crystal JD.

Behav Brain Res. 2017 Mar 1;320:48-57. doi: 10.1016/j.bbr.2016.11.042. Epub 2016 Nov 28.

4.

A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase.

Carey LM, Slivicki RA, Leishman E, Cornett B, Mackie K, Bradshaw H, Hohmann AG.

Mol Pain. 2016 May 13;12. pii: 1744806916649192. doi: 10.1177/1744806916649192. Print 2016.

5.

Impact of Genetic Reduction of NMNAT2 on Chemotherapy-Induced Losses in Cell Viability In Vitro and Peripheral Neuropathy In Vivo.

Slivicki RA, Ali YO, Lu HC, Hohmann AG.

PLoS One. 2016 Jan 25;11(1):e0147620. doi: 10.1371/journal.pone.0147620. eCollection 2016.

Supplemental Content

Loading ...
Support Center